Company intelligence / Profile preview
Maternica Therapeutics
Montreal, Quebec, Canadamaternicarx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Maternica is developing small peptide allosteric antagonists targeting IL-1 and IL-6 receptors. Preclinical data in mice and human cells show these antagonists decrease inflammation in mother and fetus, block preterm delivery, and protect the fetus from inflammatory harm[4][9].
- Therapeutic areas
- Women's Health
- Modalities
- Small peptide allosteric antagonists
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Maternica Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Maternica Therapeutics.